We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FTC Closes Antitrust Probe Of Allergan's Acular Drug

Law360 (February 13, 2004, 12:00 AM EST) -- The Federal Trade Commission has officially closed its antitrust investigation into accusations that Allergan tried to block generic competition for its Acular eye drug.

The FTC's Bureau of Competition wrapped up its probe after the U.S. District Court for the Northern District of California ruled in December that the patent covering the top-selling anti-inflammatory treatment is valid and enforceable.

The district court ruled that Apotex and some of its subsidiaries would infringe on the Acular patent by producing a proposed generic version. The antitrust action was...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.